GLP-1
Glucagon-like peptide for metabolic health and weight management
Overview
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone naturally produced in the gut. It plays a crucial role in glucose metabolism, appetite regulation, and weight management. Synthetic analogs have revolutionized obesity treatment.
Mechanism of Action
Binds GLP-1 receptors in pancreas and brain → stimulates insulin secretion → suppresses glucagon → slows gastric emptying → activates satiety centers in hypothalamus.
Benefits
- Appetite suppression
- Improved insulin sensitivity
- Blood sugar regulation
- Cardiovascular protection
- Weight loss
Dosing Protocol
Half-Life
2–5 minutes (native); hours to days (analogs)
Duration of pharmacological activity after administration.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis (rare)
Stacking Recommendations
Storage & Reconstitution
Refrigerate at 2–8°C. See specific product labeling.
Research Notes
One of the most validated targets in metabolic medicine. FDA-approved analogs include semaglutide, liraglutide, and tirzepatide. Ongoing research into oral formulations and combination therapies.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.